Drug data last refreshed Just now · AI intelligence enriched 1w ago
VASCOR (bepridil hydrochloride) is an oral calcium channel blocker approved in 1990 for angina pectoris. It reduces myocardial oxygen demand and improves coronary blood flow. The product is a small-molecule cardiovascular agent used in patients with chronic stable angina who are refractory to or intolerant of other antianginal therapies.
As LOE approaches, the brand team is likely consolidating or transitioning resources; commercial headcount may be modest and focused on managed care retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
VASCOR positions are rare due to limited commercial footprint and LOE status; opportunities are concentrated in managed care, generic transition support, and niche specialty cardiology segments. Career mobility on this product is constrained, making it a holding pattern rather than a growth lever unless combined with other cardiology portfolio assignments.
Worked on VASCOR at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.